Valion Bio Announces Final Data From Entolimod Study For Hematopoietic And Gastrointestinal Forms Of Acute Radiation Syndrome; AFRRI Study Found No Evidence Of Treatment-Related Toxicity After One Dose Of Entolimod, Supporting Advancement Toward A Fully Funded Therapeutic Study
Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation,
Valion Bio's drug entolimod passed a safety test for radiation sickness. The drug worked without causing bad side effects, which means the company can do more testing.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.